Compared to KRAS-wild-type tumors, overall KRAS-mutated cancers were less likely to exhibit poor differentiation (5.8%, P < 0.0001), MSI-high (6.2%, P < 0.0001), and BRAF mutation (1.4%, P < 0.0001), and more likely to demonstrate cecal location (24%, P < 0.0001), CIMP-low (49%, P < 0.0001), and PIK3CA mutation (24%, P < 0.0001). The gene discussed is BRAF; the disease is cancer.